Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type.
about
Selecting for BRCA1 testing using a combination of homogeneous selection criteria and immunohistochemical characteristics of breast cancersRecent translational research: microarray expression profiling of breast cancer--beyond classification and prognostic markers?Relationship of patients' age to histopathological features of breast tumours in BRCA1 and BRCA2 and mutation-negative breast cancer families.BRCA1 and estrogen/estrogen receptor in breast cancer: where they interact?A novel BRCA1 mutation in a patient with breast and ovarian cancer: A case report.Pathology and gene expression of hereditary breast tumors associated with BRCA1, BRCA2 and CHEK2 gene mutationsExamining the pathogenesis of breast cancer using a novel agent-based model of mammary ductal epithelium dynamicsEffects of estrogen on breast cancer development: Role of estrogen receptor independent mechanismsMale breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2.Hormone receptor status of contralateral breast cancers: analysis of data from the US SEER population-based registries.The prevalence of BRCA1 mutations among young women with triple-negative breast cancer.Genotype-Phenotype Correlations by Ethnicity and Mutation Location in BRCA Mutation Carriers.Effect of Prior Bilateral Oophorectomy on the Presentation of Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.Contribution of an alveolar cell of origin to the high-grade malignant phenotype of pregnancy-associated breast cancerPrevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancersA knowledge-based framework for the discovery of cancer-predisposing variants using large-scale sequencing breast cancer dataExpression of the embryonic stem cell marker SOX2 in early-stage breast carcinomaThe prevalence of BRCA1/2 mutations of triple-negative breast cancer patients in Xinjiang multiple ethnic region of China.Prediction of breast cancer sensitivity to neoadjuvant chemotherapy based on status of DNA damage repair proteins.Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic featuresHormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study populationBRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation.Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriersIncorporating tumour pathology information into breast cancer risk prediction algorithms.A simulation model to predict the impact of prophylactic surgery and screening on the life expectancy of BRCA1 and BRCA2 mutation carriers.How many etiological subtypes of breast cancer: two, three, four, or more?miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors.Tumor characteristics as an analytic tool for classifying genetic variants of uncertain clinical significance.Differing clinical impact of BRCA1 and BRCA2 mutations in serous ovarian cancer.Treatment options for patients with triple-negative breast cancerMutation analysis of BRCA1, BRCA2, PALB2 and BRD7 in a hospital-based series of German patients with triple-negative breast cancer.Immunophenotypic predictive profiling of BRCA1-associated breast cancer.The effectiveness of cucurbitacin B in BRCA1 defective breast cancer cells.Activation of estrogen signaling pathways collaborates with loss of Brca1 to promote development of ERalpha-negative and ERalpha-positive mammary preneoplasia and cancer.Early pregnancy sex steroids and maternal breast cancer: a nested case-control study.Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancerClassifications within molecular subtypes enables identification of BRCA1/BRCA2 mutation carriers by RNA tumor profiling.Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study.Clinical and pathological characteristics of Hispanic BRCA-associated breast cancers in the American-Mexican border city of El Paso, TX.Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations
P2860
Q21260381-019A717C-FC02-4513-8342-65353FB180E6Q24806447-D12CE2BA-E7C7-49DD-ACE9-37603F0A035BQ24810584-775C168E-43F6-4133-8325-C4BF93AA5D3DQ26822737-DDD7EBF5-6746-4E79-B5F4-C7520C93CA70Q27852587-5D74ADF9-6D4A-40A7-9F4C-800BB722B201Q28265304-D4DC4909-575D-487C-92EA-A20858B89113Q28383242-F6D9C0E1-C1A3-405C-90B1-05DA8821C73BQ30360376-330F5E68-6F4D-417E-8F25-147D557806E3Q31043651-DD1029EC-675A-4409-8215-46B7EBB38450Q31120324-4051B881-C643-4006-B377-62C9820F1AB0Q33419708-92402B62-1D78-4D49-9B29-533C95FF6B3CQ33620683-14E28722-4D1D-4848-85D6-B2FE600E158CQ33722531-674BAB2F-C2C7-41C1-8135-28F66C09E1E7Q33728569-0AF7FEDF-D8A5-4000-B310-51393F79DFA7Q33748161-B24EDDF2-A58A-4B2F-A777-87A6CEDAC8B6Q33750026-50B47DDC-C48A-44F1-BBEA-D35FC2B470F4Q33806378-532009FA-D02C-4919-8903-3721722E0678Q33826713-1CF28309-B4A5-4B93-A2BF-1DDFC7838673Q33889482-A681175C-993A-44A8-9B94-1B93ADBA2DA8Q33892942-1161CC6D-6C2F-485A-ABB9-C38903873AD7Q33919320-08ED17B2-665C-4403-ABBC-662A6ECCB6D6Q33930051-3B769B7E-1F47-4D01-B18D-4AA574CED026Q34039438-59759458-90FC-45D7-AEEC-1B7E30D92E98Q34048046-BDA4E901-F47D-4A35-AA38-07612046FD12Q34097351-24AE8FF5-0E6B-440E-AB18-BA5792853238Q34106175-EF847832-6812-4636-ABA9-63B1A334A80BQ34157084-28701685-8178-46A3-A64F-32923EAF9B37Q34252077-A8E24273-0A50-4A2B-95B5-20D6917851E3Q34305493-6DAA5D07-D9A1-4EEC-849E-519BFFA400BDQ34331406-591F55AD-2A22-41EC-B5E0-178440A7EE32Q34460831-B28350E9-DA85-4DAC-9178-338A9C70E1EBQ34467646-E5D2A1F0-84CC-41BC-BF9C-8371A7EAB6FAQ34581026-6B74E70E-9463-4E13-B51D-95A40C053C58Q34609774-F5769FB8-6FCB-415A-BA93-017684C02D3DQ34621664-0FFED27C-9698-4504-B328-9371EDF916C8Q34625335-D0C84830-5C59-4A00-A495-56471871B7ECQ34738030-769AA8E0-755C-4606-81BF-445610E8FD2EQ34749278-BE8FFBC7-C19B-454C-BE08-C8B7CEEA8585Q34991306-24217EF6-6D0D-4AD8-A586-4D64C5151880Q35100315-47BC2351-50E8-40CC-ABF1-5FB2A8D9D931
P2860
Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type.
description
2004 nî lūn-bûn
@nan
2004 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի մարտին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Estrogen receptor status in BR ...... grade, and histological type.
@ast
Estrogen receptor status in BR ...... grade, and histological type.
@en
Estrogen receptor status in BR ...... grade, and histological type.
@nl
type
label
Estrogen receptor status in BR ...... grade, and histological type.
@ast
Estrogen receptor status in BR ...... grade, and histological type.
@en
Estrogen receptor status in BR ...... grade, and histological type.
@nl
prefLabel
Estrogen receptor status in BR ...... grade, and histological type.
@ast
Estrogen receptor status in BR ...... grade, and histological type.
@en
Estrogen receptor status in BR ...... grade, and histological type.
@nl
P2093
P50
P1476
Estrogen receptor status in BR ...... grade, and histological type.
@en
P2093
Barbara L Weber
Henry T Lynch
Ivo A Olivotto
Jane McLennan
Kelly Metcalfe
Louis R Bégin
Nadine Tung
Parviz Ghadirian
Wedad M Hanna
P304
P356
10.1158/1078-0432.CCR-03-1061
P407
P577
2004-03-01T00:00:00Z